title: [Therapeutic adherence to oral cancer therapy and interdisciplinary management].
abstract: Medication adherence is a well-known risk factor in internal medicine. However in oncology this dimension is emerging due to the increasing number of oral formulations. First results in the oral oncology literature suggest that patients' ability to cope with medical prescription decreases with time. This might preclude patients from reaching clinical outcomes. Factors impacting on medication adherence to oral oncology treatments have not been yet extensively described neither strategies to address them and support patient's needs. Oncologists and pharmacists in our University outpatient settings performed a pilot study which aimed at measuring and facilitating adherence to oral oncology treatments and at understanding determinants of patient's adherence. The ultimate purpose of such a patient-centered and interdisciplinary collaboration would be to promote patient self-management and complement the standard medical follow-up.
authors: Centre pluridisciplinaire d'oncologie, CHUV, Lausanne. leila.achtari@chuv.ch
authors: L Achtari
authors: LA
authors: Jeanneret
authors: M P
authors: MP
authors: Schneider
authors: S
authors: S
authors: Troxler
authors: O
authors: O
authors: Bugnon
authors: F
authors: F
authors: Lüthi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000284:Administration, Oral; D000368:Aged; D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D000069287:Capecitabine; D002430:Cecal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D033183:Interdisciplinary Communication; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D010045:Outpatients / Q000706:statistics & numerical data; D018802:Patient-Centered Care / Q000706:statistics & numerical data; D010595:Pharmacists; D010819:Physician's Role; D010865:Pilot Projects; D010879:Piperazines / Q000008:administration & dosage; D011446:Prospective Studies; D011743:Pyrimidines / Q000008:administration & dosage; D013557:Switzerland / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome; D016903:Drug Monitoring
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D003841:Deoxycytidine; D000069287:Capecitabine; D000068877:Imatinib Mesylate; D005472:Fluorouracil